IL-17 Inhibition with Secukinumab in PsA: X-Ray Outcomes

Save

With the emergence of new MOAs for the treatment of psoriatic arthritis in recent years, the most burning question remained if newer agents would perform as well in terms of radiographic progression as they did in clinical domains.

Podcast of ACR17 Day 2

Save

Check out this compilation of our ACR17 Day 2 videocasts merged into a one hour podcast !

Low-dose Bactrim Safe with Methotrexate in AAV

Save

A high proportion of GPA patients receive pneumocystis prophylaxis, usually with TMP-SMX (Bactrim), and drug interactions are always a concern.  

Co-morbid Fibromyalgia

Save

ACR 2017 - Day 1 Highlights

Save

Curtis and colleagues presented a plenary session that analyzed the duration of drug holidays and the risk of subsequent fractures (FX) in women starting bisphosphonates (BP).

Increasing Incidence of Paradoxical Autoimmune Disease with Biologics?

Save

With the increasing use of biologic therapies to treat rheumatic disease has come an awareness of a small but real risk of developing de novo autoimmune disease.

Romosozumab vs Alendronate in Postmenopausal Osteoporosis

Save

Poster 318 presented at the ACR on Sunday morning caught attention of many, highlighting updates in phase 3 active controlled study of romosozumab vs alendronate in patients with postmenopausal osteoporosis with high risk of fracture.

BMS Featured Presentations from ACR 2017

Save

Bristol-Myers Squibb Company confirmed that 34 abstracts related to ORENCIA® (abatacept) and the Company’s immunoscience pipeline will be presented at the 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting, November 3-8, 2017, in San Diego.

Novartis Features Secukinumab Data at ACR 17

Save

Novartis has announce it will present its long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting

Abbvie's Robust ACR Presentations

Save

AbbVie announced that data from 38 abstracts of HUMIRA® (adalimumab) and the company's portfolio of investigational immunology medicines will be presented at the 2017 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) Annual Meeting, November 3-8, in S

Lilly's New Data at ACR 2017

Save

Eli Lilly and Company (NYSE: LLY) announced that it will present new data for baricitinib and Taltz® (ixekizumab) at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting taking place Nov. 3-8, 2017, in San Diego, Calif.

Ironwood Featured Presentations

Save

Ironwood Pharmaceuticals, Inc. (IRWD) today announced one oral and twelve poster presentations to be presented at the upcoming ACR/ARHP Annual Meeting in San Diego, California from November 3-8, 2017.

CALM Study: Tight Control with Anti-TNF Wins in Crohn's Disease

Save

Not unlike rheumatoid arthritis and other inflammatory disorders, therapeutic efficacy in Crohn's disease (CD) is often assessed clinically. There is growing use and interest in biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein.

NSAID and Opioid Adverse Event Reports from MedWatch

Save

One-third of adults in the USA experience chronic pain and take prescription nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or opioids.

Tocilizumab Benefits Persist in SSc

Save

Clinically meaningful improvements in systemic sclerosis among patients treated with subcutaneous tocilizumab (Actemra) persisted during the open-label phase of a multinational randomized phase II trial, researchers reported.

New EULAR/ACR Classification Criteria for Adult and Juvenile Myositis

Save

The European League Against Rheumatism and the American College of Rheumatology (EULAR/ACR) have developed classification criteria for idiopathic inflammatory myopathies (IIM) based on data from 976 IIM patients (74% adults; 26% children) and 624 non-IIM patients with mimicking conditions (82% ad

Death Rates from Lupus Remain Disproportionately High

Save

The Annals of Internal Medicine reports that despite improving trends in mortality, death rates from systematic lupus erythematosus (lupus) remain high compared to those in the general population, and disparities persist between subpopulations and geographic regions. Underreporting of lupus on death certificates may have resulted in underestimates of mortality rates. 

CRIB Study Shows No Transplacental Transfer of Certolizumab

Save

Mariette and colleagues have reported on the prospective pharmacokinetic study of placental transfer of certolizumab pegol (CZP) from pregnant women to their infants at the time of birith.

CDC Endorses New Shingles Vaccine Over Zostavax

Save

The  U.S. Centers for Disease Control (CDC) announced on 25 October they endorsed the use of the new GSK shingles vaccine (Shingrix) over the currently available live-virus vaccine (Zostavax) from Merck. 

RABBIT Risk Scores are Higher in ICU-Admitted RA Patients

Save

The German Rheumatoid Arthritis Biologics Registry (RABBIT) has developed an infectious risk calculator that can project a patient's risk of serious infection in the next 6 months based on several key factors - age, Prior DMARDs, prednisone dose, comorbidities and the biologic intended for use.&n